JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB312774

Alexa Fluor® 568 Anti-PIAS1 抗体 [EPR2580(2)]

Alexa Fluor® 568 Anti-PIAS1 antibody [EPR2580(2)]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal PIAS1 antibody - conjugated to Alexa Fluor® 568.

別名を表示する

DDXBP1, PIAS1, E3 SUMO-protein ligase PIAS1, DEAD/H box-binding protein 1, E3 SUMO-protein transferase PIAS1, Gu-binding protein, Protein inhibitor of activated STAT protein 1, RNA helicase II-binding protein, GBP

関連する標識済み抗体及び組成の異なる製品 (9)

  • Unconjugated

    Anti-PIAS1 antibody [EPR2580(2)]

  • 660 APC

    APC Anti-PIAS1 antibody [EPR2580(2)]

  • HRP

    HRP Anti-PIAS1 antibody [EPR2580(2)]

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-PIAS1 antibody [EPR2580(2)]

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-PIAS1 antibody [EPR2580(2)]

  • 578 PE

    PE Anti-PIAS1 antibody [EPR2580(2)]

  • Carrier free

    Anti-PIAS1 antibody [EPR2580(2)] - BSA and Azide free

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-PIAS1 antibody [EPR2580(2)]

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-PIAS1 antibody [EPR2580(2)]

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EPR2580(2)

アイソタイプ

IgG

標識

Alexa Fluor® 568

励起波長/蛍光波長

Ex: 578nm, Em: 603nm

キャリアフリー

No

アプリケーション

Antibody Labelling, Target Binding Affinity

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

製品の詳細

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle|Store in the dark

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

PIAS1 also known as Protein Inhibitor of Activated STAT 1 functions as a E3 SUMO-protein ligase which regulates protein function and localization through sumoylation. It has a molecular mass of approximately 70 kDa. PIAS1 is widely expressed in a variety of tissues indicating its involvement in diverse cellular functions. This protein binds to target proteins and modulates their activity impacting how cells respond to different stimuli.
Biological function summary

PIAS1 influences transcription regulation and gene expression. It acts as a transcriptional co-regulator by interacting with various transcription factors and modulating their activity. PIAS1 is part of multiprotein complexes that mediate these regulatory processes. Its activity is important for maintaining a balanced gene expression which if uncontrolled may result in abnormal cell behavior.

Pathways

PIAS1 plays an important role in signal transduction pathways such as the JAK/STAT pathway and the NF-kB signaling pathway. It interacts with proteins like STAT an important component in these pathways to regulate immune responses and cell growth. PIAS1 modulates the activity of these pathways in part by the covalent attachment of the small ubiquitin-like modifier (SUMO) proteins demonstrating its importance in cellular signaling networks.

PIAS1 relates closely to cancer progression and autoimmune diseases. Abnormal PIAS1 function or expression has links to certain cancers due to its role in controlling cell proliferation and differentiation. In autoimmune disorders PIAS1 affects immune regulation through its interaction with Signal Transducer and Activator of Transcription proteins showing altered activity in diseases like rheumatoid arthritis. Understanding PIAS1's contributions to these pathological states helps in developing targeted therapies.

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

ターゲットの情報

Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor (PubMed : 11583632, PubMed : 11867732, PubMed : 14500712, PubMed : 21965678, PubMed : 36050397). Catalyzes sumoylation of various proteins, such as CEBPB, MRE11, MTA1, PTK2 and PML (PubMed : 11583632, PubMed : 11867732, PubMed : 14500712, PubMed : 21965678, PubMed : 36050397). Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway (PubMed : 11583632, PubMed : 11867732). In vitro, binds A/T-rich DNA (PubMed : 15133049). The effects of this transcriptional coregulation, transactivation or silencing, may vary depending upon the biological context (PubMed : 11583632, PubMed : 11867732, PubMed : 14500712, PubMed : 21965678, PubMed : 36050397). Mediates sumoylation of MRE11, stabilizing MRE11 on chromatin during end resection (PubMed : 36050397). Sumoylates PML (at 'Lys-65' and 'Lys-160') and PML-RAR and promotes their ubiquitin-mediated degradation (By similarity). PIAS1-mediated sumoylation of PML promotes its interaction with CSNK2A1/CK2 which in turn promotes PML phosphorylation and degradation (By similarity). Enhances the sumoylation of MTA1 and may participate in its paralog-selective sumoylation (PubMed : 21965678). Plays a dynamic role in adipogenesis by promoting the SUMOylation and degradation of CEBPB (By similarity). Mediates the nuclear mobility and localization of MSX1 to the nuclear periphery, whereby MSX1 is brought into the proximity of target myoblast differentiation factor genes (By similarity). Also required for the binding of MSX1 to the core enhancer region in target gene promoter regions, independent of its sumoylation activity (By similarity). Capable of binding to the core enhancer region TAAT box in the MYOD1 gene promoter (By similarity).. (Microbial infection) Restricts Epstein-Barr virus (EBV) lytic replication by acting as an inhibitor for transcription factors involved in lytic gene expression (PubMed : 29262325). The virus can use apoptotic caspases to antagonize PIAS1-mediated restriction and express its lytic genes (PubMed : 29262325).
See full target information PIAS1

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com